Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Sensitivity to Therapy

In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis

Leukemia volume 14, pages 379–388 (2000)Cite this article

Abstract

Fludarabine phosphate (2-F-ara-AMP) is an adenine nucleoside analogue that shows significant activity against chronic lymphocytic leukemia and indolent lymphoma. We assessed the cytotoxic interaction produced by the combination of the active metabolite of fludarabine phosphate, fludarabine (9-β-D-arabinofuranosyl-2-fluoroadenine, 2-F-ara-A), and some commonly used antileukemic agents against human hairy cell leukemia cell line JOK-1, human chronic lymphocytic leukemia cell line SKW-3, and adult T cell leukemia cell lines ED-40810 (−) and SALT-3. The leukemia cells were exposed simultaneously to 2-F-ara-A and to the other agents for 4 days. Cell growth inhibition was determined using MTT reduction assay. The isobologram method of Steel and Peckham was used to evaluate the cytotoxic interaction. 2-F-ara-A and cytarabine showed synergistic effects in SKW-3 cells, additive and synergistic effects in JOK-1 and SALT-3 cells, and additive effects in ED-40810(−) cells. 2-F-ara-A and doxorubicin showed additive effects in SKW-3, ED-40810(−) and SALT-3 cell lines, and additive and synergistic effects in JOK-1 cells. 2-F-ara-A showed additive effects with etoposide, 4-hydroperoxy-cyclophosphamide, and hydroxyurea in all four cell lines. 2-F-ara-A showed antagonistic effects with methotrexate and vincristine in all four cell lines. Our findings suggest that the simultaneous administration of fludarabine phosphate with cytarabine, doxorubicin, etoposide, cyclophosphamide, or hydroxyurea would be advantageous for cytotoxic effects. Among these agents, cytarabine may be the best agent for the combination with fludarabine phosphate. The simultaneous administration of fludarabine phosphate with methotrexate or vincristine would have little cytotoxic effect, and this combination may be inappropriate. These findings may be useful in clinical trials of combination chemotherapy with fludarabine phosphate and these agents.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Brockton RW, Cheng YC, Stabile FM Jr, Montgomery JA . Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase Cancer Res 1980 40: 3610–3615

    Google Scholar 

  2. Avramis VI, Plunkett W . Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388 Cancer Res 1982 42: 2587–2591

    CAS  PubMed  Google Scholar 

  3. Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL Jr . In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells Mol Pharmacol 1982 21: 474–477

    CAS  PubMed  Google Scholar 

  4. Huang P, Chubb S, Plunkett W . Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity J Biol Chem 1990 265: 16617–16625

    CAS  PubMed  Google Scholar 

  5. Plunkett W, Huang P, Gandhi V . Metabolism and action of fludarabine phosphate Semin Oncol 1990 17: (Suppl. 8) 3–17

    CAS  PubMed  Google Scholar 

  6. Kamiya K, Huang P, Plunkett W . Inhibition of the 3′ → 5′ exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA J Biol Chem 1996 271: 19428–19435

    Article  CAS  Google Scholar 

  7. Hutton JJ, Von Hoff DD, Kuhn J, Phillip J, Hersh M, Clark G . Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite Cancer Res 1984 44: 4183–4186

    CAS  PubMed  Google Scholar 

  8. Leiby JM, Grever MR, Staubus AE, Neidhart JA . Malspeis L. Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule J Natl Cancer Inst 1988 80: 447–449

    Article  CAS  Google Scholar 

  9. Leiby JM, Snider KM, Kraut EH, Metz EN, Malspeis L, Grever MR . Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity Cancer Res 1987 47: 2719–2722

    CAS  PubMed  Google Scholar 

  10. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB . Fludarabine: a new agent with major activity against chronic lymphocytic leukemia Blood 1989 74: 19–25

    CAS  PubMed  Google Scholar 

  11. Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, Mccredie KB . Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia J Clin Oncol 1991 9: 44–49

    Article  CAS  Google Scholar 

  12. Hiddemann W . Non-Hodgkin's lymphomas – current status of therapy and future perspectives Eur J Cancer 1995 31A: 2141–2145

    Article  CAS  Google Scholar 

  13. Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH . Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group J Clin Oncol 1997 15: 2780–2785

    Article  CAS  Google Scholar 

  14. Whelan JS, Davis CL, Rule S, Ranson M, Smith OP, Mehta AB, Catovsky D, Rohatiner AZ, Lister TA . Fludarabine phosphate for the treatment of low grade lymphoid malignancy Br J Cancer 1991 64: 120–123

    Article  CAS  Google Scholar 

  15. Elias L, Stock-Novack D, Head DR, Grever MR, Weick JK, Chapman RA, Godwin JE, Metz EN, Appelbaum FR . A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study Leukemia 1993 7: 361–365

    CAS  PubMed  Google Scholar 

  16. Gandhi V, Estey E, Keating MJ, Plunkett W . Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy J Clin Oncol 1993 11: 116–124

    Article  CAS  Google Scholar 

  17. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, Pierre S, Freireich EJ, Deisseroth A, Keating MJ . Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor J Clin Oncol 1994 12: 671–678

    Article  CAS  Google Scholar 

  18. Foss FM, Ihde DC, Linnoila IR, Fischmann AB, Schechter GP, Cotelingam JD, Steinberg SM, Ghosh BC, Stocker JL, Bastian A, Phares JC, Sausville FA . Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome J Clin Oncol 1994 12: 2051–2059

    Article  CAS  Google Scholar 

  19. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ . Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia Leukemia 1995 9: 943–945

    CAS  PubMed  Google Scholar 

  20. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F . Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma J Clin Oncol 1996 14: 1262–1268

    Article  CAS  Google Scholar 

  21. Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH . Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group J Clin Oncol 1997 15: 2780–2785

    Article  CAS  Google Scholar 

  22. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ . Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia Br J Haematol 1997 99: 939–944

    Article  CAS  Google Scholar 

  23. Younes A, Rodriguez MA, McLaughlin P, North L, Sarris AH, Pate O, Hagemeister FB, Romaguera J, Preti A, Bachier C, Cabanillas F . Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma Leuk Lymphoma 1997 26: 77–82

    Article  CAS  Google Scholar 

  24. Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M . Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas Eur J Haematol 1997 59: 327–328

    Article  CAS  Google Scholar 

  25. Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kowck R, Reaman GH, Sato JK . Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group Clin Cancer Res 1998 4: 45–52

    CAS  PubMed  Google Scholar 

  26. Sato A, Montgomery JA, Cory JG . Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole Cancer Res 1984 44: 3286–3290

    CAS  PubMed  Google Scholar 

  27. Gandhi V, Plunkett W . Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells Cancer Res 1988 48: 329–334

    CAS  PubMed  Google Scholar 

  28. Rayappa C, McCulloch EA . A cell culture model for the treatment of acute myeloblastic leukemia with fludarabine and cytosine arabinoside Leukemia 1993 7: 992–999

    CAS  PubMed  Google Scholar 

  29. Yang LY, Li L, Keating MJ, Plunkett W . Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair Mol Pharmacol 1995 47: 1072–1079

    CAS  PubMed  Google Scholar 

  30. Loughlin S, Gandhi V, Plunkett W, Zwelling LA . The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells Cancer Chemother Pharmacol 1996 38: 261–268

    Article  CAS  Google Scholar 

  31. Li L, Liu X, Glassman AB, Keating MJ, Stros M, Plunkett W, Yang LY . Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance Mol Pharmacol 1997 52: 798–806

    Article  CAS  Google Scholar 

  32. Bellosillo B, Colomer D, Pons G, Gil J . Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells Br J Haematol 1998 100: 142–146

    Article  CAS  Google Scholar 

  33. Koehl U, Li L, Nowak B, Ruiz van Haperen V, Kornhuber B, Schwabe D, O'Brien S, Keating M, Plunkett W, Yang LY . Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal Proc Am Assoc Cancer Res 1997 38: 2

    Google Scholar 

  34. Kano Y, Sakamoto S, Kakahara T, Akutsu M, Inoue Y, Miura Y . In vitro effects of amsacrine in combination with other anti-cancer agents Leukemia Res 1991 15: 1059–1066

    Article  CAS  Google Scholar 

  35. Steel GG, Peckham MJ . Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity Int J Radiat Oncol Biol Phys 1979 5: 85–93

    Article  CAS  Google Scholar 

  36. Kontula K, Paavonen T, Vuopio P, Andersson LC . Glucocorticoid receptors in hairy-cell leukemia Int J Cancer 1982 30: 423–426

    Article  CAS  Google Scholar 

  37. Erikson J, Finger L, Sun L, ar-Rushdi A, Nishikura K, Minowada J, Finan J, Emanuel BS, Nowell PC, Croce CM . Deregulation of c-myc by translocation of the alpha-locus of the T-cell receptor in T-cell leukemias Science 1986 232: 884–886

    Article  CAS  Google Scholar 

  38. Maeda M, Shimizu A, Ikuta K, Okamoto H, Kashihara M, Uchiyama T, Honjo T, Yodoi J . Origin of human T-lymphotrophic virus I-positive T cell lines in adult T cell leukemia J Exp Med 1985 162: 2169–2174

    Article  CAS  Google Scholar 

  39. Sagawa K, Koga T, Sasaguri Y, Sadamori N, Nagai K . A novel adult T cell leukemia-derived cell line (SALT-3) susceptible to human immunodeficiency virus type 1 infection Kurume Med J 1995 42: 149–160

    Article  CAS  Google Scholar 

  40. Kano Y, Ohnuma T, Okano T, Holland JF . Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture Cancer Res 1988 48: 351–356

    CAS  PubMed  Google Scholar 

  41. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y . Effects of CPT-11 in combination with other anti-cancer agents in culture Int J Cancer 1992 50: 604–610

    Article  CAS  Google Scholar 

  42. Kano Y, Akutsu M, Tsunoda S, Suzuki K, Adachi K . In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines Cancer Chemother Pharmacol 1998 42: 91–98

    Article  CAS  Google Scholar 

  43. Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M . Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas Eur J Haematol 1997 59: 327–328

    Article  CAS  Google Scholar 

  44. Frewin R, Turner D, Tighe M, Davies S, Rule S, Johnson S . Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders Br J Cancer 1999 104: 612–613

    CAS  Google Scholar 

  45. Kapelushnik J, Or R, Slavin S, Nagler A . A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia Bone Marrow Transplant 1997 201: 109–110

    Google Scholar 

  46. Krakoff I, Brown NC, Reichard P . Inhibition of ribonucleoside diphosphate reductase by hydroxyurea Cancer Res 1968 28: 1559–1565

    CAS  PubMed  Google Scholar 

  47. Lundberg JM, Matthaeus WG, Chitamber CR . Gallium nitrate and fludarabine in combination synergistically inhibit the proliferation of human leukemia HL60 cells Pro Am Soc Clin Oncol 1990 9: 77

    Google Scholar 

  48. Cory JG, Sato A, Carter GL, Bacon PE, Montgomery JA, Brown NC . The utility of combinations of drugs directed at specific sites of the same target enzyme-ribonucleotide reductase as the model Adv Enzyme Regul 1985 23: 181–192

    Article  CAS  Google Scholar 

  49. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC . bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia Blood 1993 82: 1820–1828

    CAS  PubMed  Google Scholar 

  50. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T . p53 status and the efficacy of cancer therapy in vivo Science 1994 266: 807–810

    Article  CAS  Google Scholar 

  51. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P . p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies Blood 1994 84: 3148–3157

    CAS  PubMed  Google Scholar 

  52. Miyashita T, Reed JC . Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line Blood 1993 81: 151–157

    CAS  PubMed  Google Scholar 

  53. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW . Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance Oncogene 1996 12: 1055–1062

    CAS  PubMed  Google Scholar 

  54. Huang P, Plunkett W . Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event Cancer Chemother Pharmacol 1995 3: 181–188

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported in part by a Grant-in-Aid for Cancer Research (11-8) from the Ministry of Health and Welfare, Japan.

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Tochigi Cancer Center, Tochigi, Japan

    Y Kano, M Akutsu & S Tsunoda

  2. Division of Laboratory Medicine, Tochigi Cancer Center, Tochigi, Japan

    K Suzuki & A Ichikawa

  3. Department of Hematology, Center for Molecular Medicine, Jichi Medical School, Tochigi, Japan

    Y Furukawa

  4. Research Department, Nihon Schering Co. Ltd., Osaka, Japan

    L Bai & K Kon

Authors
  1. Y Kano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Akutsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Tsunoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Ichikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Kon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kano, Y., Akutsu, M., Tsunoda, S. et al. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis. Leukemia 14, 379–388 (2000). https://doi.org/10.1038/sj.leu.2401684

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401684

Keywords

Search

Advanced search

Quick links